Lincoln Pharmaceuticals profit and loss

Latest FY26

Revenue: ₹671cr+7.7% on FY25
EBITDA: ₹97.7cr−3.8% on FY25
Net profit: ₹87.9cr+6.7% on FY25
EPS: ₹43.88+6.7% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	722	671	623	581	510	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	44.7	33.5	22.5	34.4	22.5
	767	704	646	615	533
	257	240	214	201	177
	89.3	79.0	68.5	82.9	68.6
	1.3	−7.4	8.8	−5.7	−4.2
	128	125	112	103	93.2
	1.1	1.0	1.9	1.5	2.0
	15.2	14.5	12.9	10.6	9.2
	147	137	118	99.4	86.5
	639	589	537	493	432
	99.6	97.7	101	99.9	89.2
	84.4	83.2	88.6	89.3	80.0
Profit
	128	116	109	122	100
	128	116	109	122	100
	29.5	27.8	25.3	25.4	26.0
	1.6	−0.0	1.5	3.5	1.6
	31.1	27.7	26.8	28.9	27.6
	96.9	87.9	82.3	93.3	72.9
	96.9	87.9	82.3	93.3	72.9
	2.5	1.7	0.1	0.1	−0.3
	99.4	89.6	82.4	93.4	72.6
	—	87.9	82.3	93.3	72.9
Per share
	₹48.38	₹43.88	₹41.11	₹46.58	₹36.40
	₹48.38	₹43.88	₹41.11	₹46.58	₹36.40
Other comprehensive income — detail
	2.5	1.7	0.1	—	—
	−2.5	−1.7	−0.1	—	—
	—	—	82.4	93.3	72.9
Per share — as-filed variants
	₹48.38	₹43.88	₹41.11	₹46.58	₹36.40
	₹48.38	₹43.88	₹41.11	₹46.58	₹36.40
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	374	360	332	302	269
	51.8%	53.6%	53.3%	52.1%	52.7%
Adjusted (ex-exceptional items) — derived
	128	116	109	122	100
	96.9	87.9	82.3	93.3	72.9
	₹48.38	₹43.88	₹41.11	₹46.58	₹36.40

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

LINCOLN₹558.10

Lincoln Pharmaceuticals Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSIGACHI THEMISMED BAJAJHCARE AMRUTANJANJAGSNPHARM WANBURY AHCLMcap ₹1,118 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	510.3	580.5	623.2	671.0	722.2
Other Income	22.5	34.4	22.5	33.5	44.7
Total Income	532.8	615.0	645.7	704.5	767.0
Expenses
+ Cost of Materials Consumed	177.0	201.1	213.9	239.6	257.5
+ Purchases of Stock-in-Trade	68.6	82.9	68.5	79.0	89.3
+ Changes in Inventories	-4.2	-5.7	8.8	-7.4	1.3
+ Employee Benefit Expense	93.2	102.9	112.5	125.2	127.7
+ Finance Costs	2.0	1.5	1.9	1.0	1.1
+ Depreciation & Amortisation	9.2	10.6	12.9	14.5	15.2
+ Other Expenses	86.5	99.4	118.0	137.0	146.9
Total Expenses	432.3	492.7	536.5	588.9	639.0
EBITDA	89.2	99.9	101.5	97.7	99.6
EBIT	80.0	89.3	88.6	83.2	84.4
Profit
PBT before Exceptional Items	100.5	122.2	109.2	115.6	128.0
Pretax Income	100.5	122.2	109.2	115.6	128.0
+ Current Tax	26.0	25.4	25.3	27.8	29.5
+ Deferred Tax	1.6	3.5	1.5	-0.0	1.6
Tax Expense	27.6	28.9	26.8	27.7	31.1
Net Income	72.9	93.3	82.3	87.9	96.9
+ Net Income — Continuing Ops	72.9	93.3	82.3	87.9	96.9
+ Other Comprehensive Income	-0.3	0.1	0.1	1.7	2.5
Total Comprehensive Income	72.6	93.4	82.4	89.6	99.4
Net Income to Common	72.9	93.3	82.3	87.9	—
Per Share
Basic EPS	36.40	46.58	41.11	43.88	48.38
Diluted EPS	36.40	46.58	41.11	43.88	48.38
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	0.1	1.7	2.5
+ Tax on Items NOT to be Reclassified	—	—	-0.1	-1.7	-2.5
Comprehensive Income — Owners of Parent	72.9	93.3	82.4	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	36.40	46.58	41.11	43.88	48.38
Diluted EPS — Continuing Operations	36.40	46.58	41.11	43.88	48.38
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	268.9	302.2	331.9	359.9	374.2
Gross Margin %	52.70	52.06	53.26	53.63	51.81
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	100.5	122.2	109.2	115.6	128.0
Net Income Adj (tax-effected)	72.9	93.3	82.3	87.9	96.9
EPS Adj	36.40	46.58	41.11	43.88	48.38
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	20.0	20.0	20.0	20.0	20.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.